FAQ: Soligenix Updates Medical Advisory Board for HyBryte™ Phase 3 CTCL Development
Summary
Soligenix has updated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL) to support the ongoing Phase 3 development of HyBryte™. This strategic move reinforces the company's commitment to advancing regulatory and commercialization activities for this novel photodynamic therapy targeting rare diseases with unmet medical needs.
What is the main announcement from Soligenix?
Soligenix has updated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL) to support the ongoing Phase 3 development of HyBryte™ (synthetic hypericin), a photodynamic therapy. The board comprises leading dermatologic and oncologic experts who will provide strategic guidance for regulatory and commercialization activities.
What is HyBryte™ and what condition does it treat?
HyBryte™ (SGX301 or synthetic hypericin sodium) is a novel photodynamic therapy that utilizes safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). It’s being developed as part of Soligenix’s Specialized BioTherapeutics business segment for rare diseases with unmet medical needs.
Why is updating the Medical Advisory Board significant?
The addition of new key opinion leaders reinforces the clinical depth of the HyBryte™ program and demonstrates Soligenix’s commitment to bringing this treatment to CTCL patients worldwide. The board provides strategic guidance as the company advances regulatory and commercialization activities.
What is the current development status of HyBryte™?
HyBryte™ has successfully completed the second Phase 3 study, and Soligenix is now advancing regulatory approvals to support potential commercialization worldwide. The company is also expanding synthetic hypericin (SGX302) into psoriasis treatment.
What other products is Soligenix developing?
Beyond HyBryte™, Soligenix is developing dusquetide (SGX942) for inflammatory diseases including oral mucositis, SGX945 for Behcet’s Disease, and vaccine programs including RiVax® for ricin toxin, filovirus vaccines, and CiVax™ for COVID-19 prevention using their ThermoVax® heat stabilization technology.
Where can investors find more information about Soligenix?
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX. The full press release can be viewed at https://ibn.fm/R32rm.
What is BioMedWire and its role in this announcement?
BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences developments. It’s part of the Dynamic Brand Portfolio within IBN that provides wire solutions and content distribution services for companies like Soligenix.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 251940